Publications by authors named "Jill L Kinzer"
Article Synopsis
- FDA-approved anti-TNFα biopharmaceuticals, like Humira®, Remicade®, and Simponi Aria®, are effective in treating autoimmune diseases, but their effectiveness varies due to product-specific differences.
- The study characterizes the structural differences in these mAbs, revealing that Remicade® has the most afucosylated glycans and unique glycans, while Humira® has fewer unique glycans but higher binding affinities.
- Functional tests indicate that Humira® shows the strongest potency and binding capabilities compared to the other two mAbs, emphasizing the importance of understanding structural differences for optimizing treatment outcomes.
View Article and Find Full Text PDF